Title of article
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Author/Authors
Beatriz Grinsztejn، نويسنده , , Bach-Yen Nguyen، نويسنده , , Christine Katlama، نويسنده , , José M Gatell، نويسنده , , Adriano Lazzarin، نويسنده , , Daniel Vittecoq، نويسنده , , Charles J Gonzalez، نويسنده , , Joshua Chen، نويسنده , , Charlotte M Harvey، نويسنده , , Robin D Isaacs ، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
9
From page
1261
To page
1269
Abstract
Summary
Background
Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs. The aim of this study was to assess the safety and efficacy
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
591199
Link To Document